Key result
Administration of the IL-1 receptor antagonist anakinra was evaluated for improving peak aerobic exercise capacity and rehospitalization in recently decompensated systolic heart failure (P=0.10).
Why the study?
Does IL-1 receptor antagonist (anakinra) inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF?
RCT
Does IL-1 receptor antagonist (anakinra) inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF?
Answers are grounded in this paper and cite their sources.
BACKGROUND: An enhanced inflammatory response predicts worse outcomes in heart failure (HF). We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF. METHODS AND CONCLUSIONS: and rehospitalization for HF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01936909.
No takes yet. Share an insight, caveat, or question.
Tassell et al. (2017) conducted an RCT in recently decompensated systolic heart failure. anakinra (IL-1 receptor antagonist) was evaluated on peak aerobic exercise capacity (p==0.10). Administration of the IL-1 receptor antagonist anakinra was evaluated for improving peak aerobic exercise capacity and rehospitalization in recently decompensated systolic heart failure (P=0.10).
Synapse has enriched 10 related papers. Consider them for comparative context: